Surovatamig safety study for rheumatoid arthritis or lupus
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests surovatamig, a new experimental treatment, to see if it's safe and how the body processes it in adults with moderate-to-severe rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). It may be an option if you've tried other biologic or targeted therapies without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have rheumatoid arthritis (RA) with moderate-to-severe symptoms unresponsive to at least two previous biologic or targeted treatments.
- Alternatively, you must have lupus (SLE) with moderate-to-severe activity unresponsive to three or more standard therapies.
- Must have certain autoantibodies (like RF or ACPA for RA, or ANA for SLE).
- Cannot have serious infections, a history of certain autoimmune diseases, or be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
This study tests a new drug called HBM7020 to see how safe it is and how your body processes it. The trial includes healthy volunteers and people with autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma to understand if the drug might help reduce disease activity.
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.